Lipodystrophy

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

EMA approval · 2025-11-03
EMA Authorised: Myalepta (Metreleptin) — Chiesi Farmaceutici S.p.A.
EMA authorised Myalepta (metreleptin) for lipodystrophy, including familial partial lipodystrophy, with orphan medicine designation; the mar…